Narrator: This is Science Today. Herceptin, a targeted breast cancer therapy, was proven effective in clinical trials both as a single agent, as well as in combination with chemotherapy. Dr. Hope Rugo, who co-directs the Breast Oncology Clinical Trials program at the University of California, San Francisco, says Herceptin wouldn't be here today if it weren't for the hundreds of women who participated in clinical trials.
Rugo: Those women were randomized like the flip of a coin to standard therapy or standard therapy with Herceptin. And we, as oncologists, have a tremendous gratitude to those patients, but it's also really important for the women out there now, for our population, to understand how important it is to participate in those trials as we go forward.
Narrator: That's because although researchers may not have the answers today, future generations may benefit tomorrow.
Rugo: And these may be your daughter, or your cousin, or your sister, will benefit from the information that we get from trials that we do today, tomorrow.
Narrator: For Science Today, I'm Larissa Branin.